Cover Image
市場調查報告書

Midkine:開發中產品分析

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 371022
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Midkine:開發中產品分析 Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Pipeline Review, H1 2017
出版日期: 2017年06月13日 內容資訊: 英文 42 Pages
簡介

本報告提供以Midkine為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Midkine 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各分子類型

治療藥的開發企業

  • Cellmid Limited
  • Ribomic Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0841TDB

Summary

According to the recently published report 'Midkine - Pipeline Review, H1 2017'; Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate, activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation. It is involved in neointima formation after arterial injury and early fetal adrenal gland development.

The report 'Midkine - Pipeline Review, H1 2017' outlays comprehensive information on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Genito Urinary System And Sex Hormones, Immunology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Inflammation, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders, Bone Fracture, Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Kidney Disease, Lung Disease, Neuroblastoma, Osteoporosis, Prostate Cancer and Squamous Non-Small Cell Lung Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
  • The report reviews Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Overview
    • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Companies Involved in Therapeutics Development
    • Cellmid Ltd
    • Ribomic Inc
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Drug Profiles
    • Antisense RNAi Oligonucleotides to Inhibit Midkine for Cardiovascular Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAB-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iMDK - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IP-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IP-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Midkine for Bone Fractures - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBM-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Midkine for Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Dormant Products
  • Midkine (Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 07, 2017: Cellmid's European Midkine Patent For Alopecia Allowed
      • Jan 18, 2017: Cellmid Receives Australian Government Grant For Midkine Programme
      • Oct 05, 2016: Cellmid's Midkine Antibodies Show Anti-Tumour Activity against Brain Cancer
      • Aug 09, 2016: Cellmid: New Publication For Cellmid Midkine Antibody
      • Jun 24, 2016: Cellmid: New Publication And Patent Application For Midkine Antibody
      • Jun 23, 2015: Cellmid Collaboration To Treat Brain Cancer
      • Jun 15, 2015: Cellmid'S Humanized Midkine Antibody Drug Is Safe In Toxicology Studies
      • Jan 21, 2015: USA Patent For Midkine To Treat Heart Failure
      • Jul 15, 2014: Cellmid Granted UK Patent for Use of Midkine for Hair Growth
      • Oct 06, 2011: Cellmid Completes Humanization Of Anti-midkine Antibody In Collaboration With Antitope
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Cellmid Ltd, H1 2017
  • Pipeline by Ribomic Inc, H1 2017
  • Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top